Document:

EX-10.4

 Exhibit 10.4 

Techne Corporation 

McLaren Merger Sub, Inc. 

614 McKinley Place NE 

Minneapolis, MN 55413 

July 31, 2014 
 ProteinSimple 

3040 Oakmead Village Drive 
 Santa Clara, CA 95051 

Ladies and Gentlemen: 
 Reference is made to the Agreement and
Plan of Merger, dated June 16, 2014 (the “Agreement”), by and among Techne Corporation, a Minnesota corporation (“Parent”), McLaren Merger Sub, Inc., a Delaware corporation (“Merger Sub”),
ProteinSimple, a Delaware corporation (“ProteinSimple”), and Fortis Advisors LLC, a Delaware limited liability company, in its capacity as Securityholders’ Representative. Capitalized terms used but not defined herein have the
meanings given to such terms in the Agreement. 
 In connection with a proposed restructuring relating to ProteinSimple’s Canadian subsidiaries to be
effected following the Closing, Parent has formed a direct wholly-owned subsidiary, Techne Canada Holdings ULC, an unlimited liability corporation incorporated under the laws of British Columbia (“ULC”), and ULC has formed a direct
wholly-owned subsidiary, McLaren Reorganization Sub, a Delaware limited liability company (“LLC”). Immediately prior to the Closing, Parent, ULC and LLC will effect a series of transactions, following which Merger Sub will become a
direct wholly-owned subsidiary of LLC as of immediately prior to the Closing. 
 Parent hereby represents and warrants to ProteinSimple that each of ULC and
LLC is a disregarded entity for U.S. federal income tax purposes. Parent agrees that the foregoing representation and warranty will be deemed to be a Fundamental Representation under the Agreement. The parties agree that for purposes of determining
(i) whether Taxes are considered Pre-Closing Taxes under the Agreement and (ii) liabilities for Taxes taken into account in the calculation of Closing Date Net Working Capital, the transactions contemplated by the Mandatory Distribution
and Re-Contribution Agreement to be entered into after the Closing by Parent, ULC, LLC, ProteinSimple and 2238726 Ontario Inc., an Ontario corporation, will be deemed to have become effective and occurred after the Closing Date, and any Taxes
arising as a result of entering into or effectuating any of the steps pursuant to such agreement shall not be taken into account in the calculation of Closing Date Net Working Capital, nor shall the Company Stockholders be responsible for any
indemnification in respect of such Taxes. 
 The Merger Agreement is hereby amended to increase the Contingency Amount as set forth on Schedule A.
The parties acknowledge and agree that the additional amount added to the 

 
Contingency Amount (the “Additional Contingency Amount”) is intended to cover certain potential Unpaid Specified Transaction Expenses and other amounts set forth on Schedule
A that are not determinable as of the Closing (the “Additional Amounts”). To the extent that such Additional Amounts are determined within the time period to determine the Final Adjustment Amount under Section 1.5 of the
Agreement, then such Additional Amounts will be taken into account in the determination of the Final Adjustment Amount and the amounts payable under Section 1.5(f) and paid in accordance with such Section. To the extent that such Additional
Amounts are not determined within such time period, then the Additional Contingency Amount will not be released or distributed by the Securityholders’ Representative until the final determination of the amount of such Additional Amounts. If all
or any portion of such Additional Amounts becomes payable to a third party, then the Securityholders’ Representative will pay such amount as directed by Parent. If all or any portion of the Additional Contingency Amount is finally determined to
not be payable with respect to any Additional Amounts, then the Securityholders’ Representative may release such portion in accordance with the Agreement. 

This letter agreement shall amend the Agreement. Except as expressly set forth herein, this letter agreement shall not by implication or otherwise alter,
modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Agreement, all of which shall continue to be in full force and effect. Unless the context otherwise requires, after the execution
and delivery hereof, any reference to the Agreement shall mean the Agreement as amended hereby. 
 [Signature page follows] 

 Please execute below to acknowledge your agreement with the foregoing. 

 

			
	Very truly yours,
	
	TECHNE CORPORATION
		
	By:	 	 /s/ Charles R. Kummeth

	Name:	 	Charles R. Kummeth
	Title:	 	Chief Executive Officer
	
	MCLAREN MERGER SUB, INC.
		
	By:	 	 /s/ Charles R. Kummeth

	Name:	 	Charles R. Kummeth
	Title:	 	President

  

			
	ACKNOWLEDGED AND AGREED:
	
	PROTEINSIMPLE
		
	By:	 	  

	Name:	 	Timothy A. Harkness
	Title:	 	President and Chief Executive Officer
	
	FORTIS ADVISORS, LLC
		
	By:	 	  

	Name:	 	Ryan Simkin
	Title:	 	Managing Director

 Please execute below to acknowledge your agreement with the foregoing. 

 

			
	Very truly yours,
	
	TECHNE CORPORATION
		
	By:	 	  

	Name:	 	Charles R. Kummeth
	Title:	 	Chief Executive Officer
	
	MCLAREN MERGER SUB, INC.
		
	By:	 	  

	Name:	 	Charles R. Kummeth
	Title:	 	President

  

			
	ACKNOWLEDGED AND AGREED:
	
	PROTEINSIMPLE
		
	By:	 	 /s/ Timothy A. Harkness

	Name:	 	Timothy A. Harkness
	Title:	 	President and Chief Executive Officer
	
	FORTIS ADVISORS, LLC
		
	By:	 	  

	Name:	 	Ryan Simkin
	Title:	 	Managing Director

 [Signature Page to Letter Agreement] 

 Please execute below to acknowledge your agreement with the foregoing. 

 

			
	Very truly yours,
	
	TECHNE CORPORATION
		
	By:	 	  

	Name:	 	Charles M. Kummeth
	Title:	 	Chief Executive Officer
	
	MCLAREN MERGER SUB, INC.
		
	By:	 	  

	Name:	 	Charles M. Kummeth
	Title:	 	President

  

			
	ACKNOWLEDGED AND AGREED:
	
	PROTEINSIMPLE
		
	By:	 	  

	Name:	 	Timothy A. Harkness
	Title:	 	President and Chief Executive Officer
	
	FORTIS ADVISORS, LLC
		
	By:	 	 /s/ Ryan Simkin

	Name:	 	Ryan Simkin
	Title:	 	Managing Director

 [Signature Page to Letter Agreement] 

 Schedule A 

The Contingency Amount is increased from $500,000 to $827,016. 

$300,000 relating to disputed amounts relating to that certain letter agreement, dated August 5, 2013, between ProteinSimple and Jefferies LLC. 

$5,216 relating to amounts attributed in the Closing Consideration Spreadsheet to Barney & Barney. 

$21,800 relating to amounts attributed in the Closing Consideration Spreadsheet to Comerica Bank.EX-10.5

 Exhibit 10.5 

Techne Corporation 

Research and Diagnostics Systems, Inc. 

614 McKinley Place NE 

Minneapolis, MN 55413 

August 27, 2014 
 CyVek, Inc. 

2 Barnes Industrial Road South 
 Wallingford, CT 06492-2432 

Ladies and Gentlemen: 
 Reference is made to the Agreement of
Investment and Merger (the “Agreement”), dated as of April 1, 2014, by and among Techne Corporation, a Minnesota corporation, Research and Diagnostic Systems, Inc., a Minnesota corporation (“Parent”). Cayenne
Merger Sub, Inc., a Delaware corporation, CyVek, Inc., a Delaware corporation (the “Company”), and Citron Capital Limited (solely in its capacity as the Stockholders’ Agent). Capitalized terms used herein and not otherwise
defined herein have the meanings given to such terms in the Agreement. 
 Under Section 5.5 of the Agreement, Parent and the Company agreed to
negotiate in good faith and use commercially reasonable efforts to enter into an agreement or agreements addressing the services and obligations set forth on Appendix 1 to the Agreement within 60 days of the Investment Closing. Parent and the
Company have agreed that they will not enter into any such agreement or agreements; accordingly, the parties to the Agreement agree that no parties will have any obligations under Section 5.5 of the Agreement. 

Each of the parties hereto hereby agrees that a lease or license of up to four (4) CyPlexTM analyzers under the following terms shall each constitute
a valid lease or license of a CyPlexTM analyzer for purposes of the Commercial Milestone Achievement under the Agreement: (a) a lease or license of a CyPlexTM analyzer in exchange for a binding, irrevocable commitment by the lessee or
licensee to purchase cartridges for the CyPlexTM analyzer within five (5) years of the date of such lease or license equal to an aggregate amount that is at least 50% of the list price for the CyPlexTM analyzer at the time of such lease
or license (the “Instrument Price”) and (b) the purchase price for each such cartridge is no less than the sum of (i) the minimum price for such cartridge in order to constitute a sale for purposes of the Commercial
Milestone Achievement under Section 7.8(b)(iii) of the Agreement and (ii) the quotient of (A) the Instrument Price and (B) the number of cartridges that such lessee or licensee has committed to purchase over the term of the lease
or license of the CyPlexTM analyzer. For example, if the Company leases a CyPlexTM analyzer with an Instrument Price of $25,000 at the time of such lease and the lessee commits to purchase three hundred (300) cartridges within five
(5) years of the date of such lease, then, as long as the committed cartridge price is equal to at least $83.33 plus the minimum price for such cartridge in order to constitute a sale for purposes of the Commercial Milestone Achievement under
Section 7.8(b)(iii), such lease shall constitute a valid lease or license of a CyPlexTM analyzer for purposes of clause (a) under the definition of Commercial Milestone Achievement set forth in the Agreement even if the Company does
not charge or receive any payment in 

 
exchange for the lease of the CyPlexTM analyzer. The foregoing shall not limit or restrict the Company from otherwise leasing or licensing a CyPlexTM analyzer and receiving credit for a
valid lease or license of a CyPlexTM analyzer for purposes of the Commercial Milestone Achievement under the Agreement. 
 Each of the parties hereto
hereby agrees that (a) Genentech and Roche shall be separate, independent, unaffiliated third-party customers for purposes of Section 7.8 of the Agreement and (b) each institute within the National Institutes of Health shall be a
separate, independent, unaffiliated third-party customer for purposes of Section 7.8 of the Agreement. 
 Please execute below to acknowledge your
agreement with the foregoing. 
  

			
	Very truly yours,
	
	TECHNE CORPORATION
		
	By:	 	 
	Name:	 	
	Title:	 	
	
	RESEARCH AND DIAGNOSTIC SYSTEMS, INC.
		
	By:	 	 
	Name:	 	
	Title:	 	
	
	CAYENNE MERGER SUB, INC.
		
	By:	 	 
	Name:	 	
	Title:	 	

  

			
	ACKNOWLEDGED AND AGREED:
	
	CYVEK, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	CITRON CAPITAL LIMITED
		
	By:	 	 /s/ Daniel E. Levy

	Name:	 	DANIEL E. LEVY
	Title:	 	DIRECTOR

 restrict the Company from otherwise leasing or licensing a CyPlexTM analyzer and receiving credit for a valid
lease or license of a CyPlexTM analyzer for purposes of the Commercial Milestone Achievement under the Agreement. 
 Each of the parties hereto hereby
agrees that (a) Genentech and Roche shall be separate, independent, unaffiliated third-party customers for purposes of Section 7.8 of the Agreement and (b) each institute within the National Institutes of Health shall be a separate,
independent, unaffiliated third-party customer for purposes of Section 7.8 of the Agreement. 
 Please execute below to acknowledge your agreement with
the foregoing. 
  

			
	Very truly yours,
	
	TECHNE CORPORATION
		
	By:	 	/s/ Jim Hippel
	Name:	 	JIM HIPPEL
	Title:	 	CFO
	
	RESEARCH AND DIAGNOSTIC SYSTEMS, INC.
		
	By:	 	/s/ Frank Mortari
	Name:	 	FRANK MORTARI
	Title:	 	VP of Corporate Development
	
	CAYENNE MERGER SUB, INC.
		
	By:	 	/s/ Jim Hippel
	Name:	 	JIM HIPPEL
	Title:	 	CFO

  

			
	ACKNOWLEDGED AND AGREED:
	
	CYVEK, INC.
		
	By:	 	 /s/ Per Hellsund

	Name:	 	Per Hellsund
	Title:	 	President & CEO
	
	CITRON CAPITAL LIMITED
		
	By:	 	  

	Name:	 	
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]